ImmunoPrecise Antibodies (IPA) Projected to Post Earnings on Tuesday

ImmunoPrecise Antibodies (NASDAQ:IPA - Get Free Report) is expected to be releasing its Q4 2025 earnings data before the market opens on Tuesday, July 29th. Analysts expect ImmunoPrecise Antibodies to post earnings of ($0.02) per share and revenue of $7.89 million for the quarter.

ImmunoPrecise Antibodies Trading Up 23.1%

Shares of NASDAQ:IPA traded up $0.42 during midday trading on Thursday, hitting $2.24. 4,871,021 shares of the stock were exchanged, compared to its average volume of 4,468,110. The stock has a market capitalization of $102.50 million, a price-to-earnings ratio of -1.93 and a beta of 0.44. The company has a debt-to-equity ratio of 0.45, a quick ratio of 2.11 and a current ratio of 2.32. The business's 50-day moving average price is $1.03 and its 200 day moving average price is $0.65. ImmunoPrecise Antibodies has a 12 month low of $0.27 and a 12 month high of $2.33.

Wall Street Analyst Weigh In

IPA has been the topic of several analyst reports. Benchmark reiterated a "speculative buy" rating and issued a $3.00 target price on shares of ImmunoPrecise Antibodies in a report on Tuesday, April 1st. HC Wainwright reiterated a "buy" rating and set a $5.00 price objective on shares of ImmunoPrecise Antibodies in a research report on Friday, April 11th. Finally, Wall Street Zen upgraded shares of ImmunoPrecise Antibodies to a "sell" rating in a research report on Saturday, May 24th.

ImmunoPrecise Antibodies Company Profile

ImmunoPrecise Antibodies Ltd., together with its subsidiaries, operates as a biotherapeutic research and technology company in Canada and internationally. It provides NonaVac DNA for complex protein classes, including GPCRs and ion channels; and Rapid Prime, a positive monoclonal antibodies for generating anti-idiotypic antibodies, and producing monoclonal antibodies against conformational epitopes.